2023-04-012024-03-312024-03-31false09550549RICHMOND OSTEOPATHS LIMITED2024-10-0186220iso4217:GBPxbrli:pure095505492023-04-01095505492024-03-31095505492023-04-012024-03-31095505492022-04-01095505492023-03-31095505492022-04-012023-03-3109550549bus:SmallEntities2023-04-012024-03-3109550549bus:AuditExempt-NoAccountantsReport2023-04-012024-03-3109550549bus:AbridgedAccounts2023-04-012024-03-3109550549bus:PrivateLimitedCompanyLtd2023-04-012024-03-3109550549core:WithinOneYear2024-03-3109550549core:AfterOneYear2024-03-3109550549core:WithinOneYear2023-03-3109550549core:AfterOneYear2023-03-3109550549core:ShareCapital2024-03-3109550549core:SharePremium2024-03-3109550549core:RevaluationReserve2024-03-3109550549core:OtherReservesSubtotal2024-03-3109550549core:RetainedEarningsAccumulatedLosses2024-03-3109550549core:ShareCapital2023-03-3109550549core:SharePremium2023-03-3109550549core:RevaluationReserve2023-03-3109550549core:OtherReservesSubtotal2023-03-3109550549core:RetainedEarningsAccumulatedLosses2023-03-3109550549core:LandBuildings2024-03-3109550549core:PlantMachinery2024-03-3109550549core:Vehicles2024-03-3109550549core:FurnitureFittings2024-03-3109550549core:OfficeEquipment2024-03-3109550549core:NetGoodwill2024-03-3109550549core:IntangibleAssetsOtherThanGoodwill2024-03-3109550549core:ListedExchangeTraded2024-03-3109550549core:UnlistedNon-exchangeTraded2024-03-3109550549core:LandBuildings2023-03-3109550549core:PlantMachinery2023-03-3109550549core:Vehicles2023-03-3109550549core:FurnitureFittings2023-03-3109550549core:OfficeEquipment2023-03-3109550549core:NetGoodwill2023-03-3109550549core:IntangibleAssetsOtherThanGoodwill2023-03-3109550549core:ListedExchangeTraded2023-03-3109550549core:UnlistedNon-exchangeTraded2023-03-3109550549core:LandBuildings2023-04-012024-03-3109550549core:PlantMachinery2023-04-012024-03-3109550549core:Vehicles2023-04-012024-03-3109550549core:FurnitureFittings2023-04-012024-03-3109550549core:OfficeEquipment2023-04-012024-03-3109550549core:NetGoodwill2023-04-012024-03-3109550549core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3109550549core:ListedExchangeTraded2023-04-012024-03-3109550549core:UnlistedNon-exchangeTraded2023-04-012024-03-3109550549core:MoreThanFiveYears2023-04-012024-03-3109550549core:Non-currentFinancialInstruments2024-03-3109550549core:Non-currentFinancialInstruments2023-03-3109550549dpl:CostSales2023-04-012024-03-3109550549dpl:DistributionCosts2023-04-012024-03-3109550549core:LandBuildings2023-04-012024-03-3109550549core:PlantMachinery2023-04-012024-03-3109550549core:Vehicles2023-04-012024-03-3109550549core:FurnitureFittings2023-04-012024-03-3109550549core:OfficeEquipment2023-04-012024-03-3109550549dpl:AdministrativeExpenses2023-04-012024-03-3109550549core:NetGoodwill2023-04-012024-03-3109550549core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3109550549dpl:GroupUndertakings2023-04-012024-03-3109550549dpl:ParticipatingInterests2023-04-012024-03-3109550549dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3109550549core:ListedExchangeTraded2023-04-012024-03-3109550549dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3109550549core:UnlistedNon-exchangeTraded2023-04-012024-03-3109550549dpl:CostSales2022-04-012023-03-3109550549dpl:DistributionCosts2022-04-012023-03-3109550549core:LandBuildings2022-04-012023-03-3109550549core:PlantMachinery2022-04-012023-03-3109550549core:Vehicles2022-04-012023-03-3109550549core:FurnitureFittings2022-04-012023-03-3109550549core:OfficeEquipment2022-04-012023-03-3109550549dpl:AdministrativeExpenses2022-04-012023-03-3109550549core:NetGoodwill2022-04-012023-03-3109550549core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3109550549dpl:GroupUndertakings2022-04-012023-03-3109550549dpl:ParticipatingInterests2022-04-012023-03-3109550549dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3109550549core:ListedExchangeTraded2022-04-012023-03-3109550549dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3109550549core:UnlistedNon-exchangeTraded2022-04-012023-03-3109550549core:NetGoodwill2024-03-3109550549core:IntangibleAssetsOtherThanGoodwill2024-03-3109550549core:LandBuildings2024-03-3109550549core:PlantMachinery2024-03-3109550549core:Vehicles2024-03-3109550549core:FurnitureFittings2024-03-3109550549core:OfficeEquipment2024-03-3109550549core:AfterOneYear2024-03-3109550549core:WithinOneYear2024-03-3109550549core:ListedExchangeTraded2024-03-3109550549core:UnlistedNon-exchangeTraded2024-03-3109550549core:ShareCapital2024-03-3109550549core:SharePremium2024-03-3109550549core:RevaluationReserve2024-03-3109550549core:OtherReservesSubtotal2024-03-3109550549core:RetainedEarningsAccumulatedLosses2024-03-3109550549core:NetGoodwill2023-03-3109550549core:IntangibleAssetsOtherThanGoodwill2023-03-3109550549core:LandBuildings2023-03-3109550549core:PlantMachinery2023-03-3109550549core:Vehicles2023-03-3109550549core:FurnitureFittings2023-03-3109550549core:OfficeEquipment2023-03-3109550549core:AfterOneYear2023-03-3109550549core:WithinOneYear2023-03-3109550549core:ListedExchangeTraded2023-03-3109550549core:UnlistedNon-exchangeTraded2023-03-3109550549core:ShareCapital2023-03-3109550549core:SharePremium2023-03-3109550549core:RevaluationReserve2023-03-3109550549core:OtherReservesSubtotal2023-03-3109550549core:RetainedEarningsAccumulatedLosses2023-03-3109550549core:NetGoodwill2022-04-0109550549core:IntangibleAssetsOtherThanGoodwill2022-04-0109550549core:LandBuildings2022-04-0109550549core:PlantMachinery2022-04-0109550549core:Vehicles2022-04-0109550549core:FurnitureFittings2022-04-0109550549core:OfficeEquipment2022-04-0109550549core:AfterOneYear2022-04-0109550549core:WithinOneYear2022-04-0109550549core:ListedExchangeTraded2022-04-0109550549core:UnlistedNon-exchangeTraded2022-04-0109550549core:ShareCapital2022-04-0109550549core:SharePremium2022-04-0109550549core:RevaluationReserve2022-04-0109550549core:OtherReservesSubtotal2022-04-0109550549core:RetainedEarningsAccumulatedLosses2022-04-0109550549core:AfterOneYear2023-04-012024-03-3109550549core:WithinOneYear2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:CostValuation2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3109550549core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3109550549core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3109550549core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3109550549core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3109550549core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3109550549bus:Director12023-04-012024-03-31

RICHMOND OSTEOPATHS LIMITED

Registered Number
09550549
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2024

RICHMOND OSTEOPATHS LIMITED
Company Information
for the year from 1 April 2023 to 31 March 2024

Director

HAM-HOWES, Austen James

Registered Address

33 Park Crescent
Twickenham
TW2 6NS

Registered Number

09550549 (England and Wales)
RICHMOND OSTEOPATHS LIMITED
Balance Sheet as at
31 March 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets332,40042,000
Tangible assets412,28214,902
44,68256,902
Current assets
Debtors4,3491,581
Cash at bank and on hand57,28590,904
61,63492,485
Creditors amounts falling due within one year5(81,429)(128,345)
Net current assets (liabilities)(19,795)(35,860)
Total assets less current liabilities24,88721,042
Net assets24,88721,042
Capital and reserves
Called up share capital11
Profit and loss account24,88621,041
Shareholders' funds24,88721,042
The financial statements were approved and authorised for issue by the Director on 1 October 2024, and are signed on its behalf by:
HAM-HOWES, Austen James
Director
Registered Company No. 09550549
RICHMOND OSTEOPATHS LIMITED
Notes to the Financial Statements
for the year ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Intangible assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows: 20%
2.Average number of employees

20242023
Average number of employees during the year00
3.Intangible assets

Total

£
Cost or valuation
At 01 April 2396,000
At 31 March 2496,000
Amortisation and impairment
At 01 April 2354,000
Charge for year9,600
At 31 March 2463,600
Net book value
At 31 March 2432,400
At 31 March 2342,000
4.Tangible fixed assets

Total

£
Cost or valuation
At 01 April 2344,473
At 31 March 2444,473
Depreciation and impairment
At 01 April 2329,570
Charge for year2,621
At 31 March 2432,191
Net book value
At 31 March 2412,282
At 31 March 2314,902
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables48,45360,880
Bank borrowings and overdrafts2,92636,412
Taxation and social security2,1031,460
Accrued liabilities and deferred income27,94729,593
Total81,429128,345
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.